19/12/2018 – AB Science provides the main achievements of this restructuring. Category: 2018By Alexis BERNARD19 December 2018Tags: 2018 Partager cet article Share on LinkedInShare on LinkedIn Share on XShare on X Share on FacebookShare on Facebook Share on WhatsAppShare on WhatsApp Pin itShare on Pinterest Author: Alexis BERNARD Post navigationPreviousPrevious post:PatientsNextNext post:Acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association ConferenceRelated PostsMasitinib phase 3 study in Alzheimer’s disease has completed patient recruitment22 October 2018Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis8 October 2018First half of 2018 revenues1 October 2018Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer23 July 2018Results of the Combined General Shareholders’ Meeting held on June 29 20183 July 2018Combined General Shareholders’ Meeting held on June 29, 20183 July 2018
Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis8 October 2018
Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer23 July 2018
